Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co Ltd. have identified heterocyclic derivatives acting as Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of melanoma, Menkes disease, rheumatoid arthritis, atherosclerosis, type 1 diabetes, Huntington’s disease and Alzheimer’s disease.
Astellas Pharma Inc. has divulged proteolysis targeting chimera (PROTAC) compounds acting as GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer.
Researchers from Ascentage Pharma Group International and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized tricyclic compounds acting as inhibitor of apoptosis proteins (IAP) inhibitors reported to be useful for the treatment of cancer, AIDS, autoimmune disease, immune thrombocytopenia (idiopathic thrombocytopenic purpura), infections, psoriasis, rheumatoid arthritis, and inflammatory disorders, among others.
Scorpion Therapeutics Inc. has disclosed tetrahydroindole derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
Iambic Therapeutics Inc. (formerly Entos Inc.) has closed a $100 million series B financing. The company intends to use this funding to support continued artificial intelligence (AI) platform innovations and advance candidates into clinical development.
The activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is key for antitumor immunity. However, the development of STING agonist-based strategies in cancer has so far encountered limitations such as incomplete tumor regression or adverse effects derived from chronic activation.
A presentation given recently by Medicenna Therapeutics Corp. highlighted preclinical data for the company’s new anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy) candidate, MDNA-223, being developed as a anticancer therapeutic candidate.
Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a pore-forming protein secreted by Listeria monocytogenes to escape lysosomes.
Cancer biotech Adlai Nortye Ltd. raised $57.5 million from its U.S. IPO on Nasdaq and $40 million from a concurrent private placement, ringing up $97.5 million in funding to develop its combo immunotherapy pipeline.
Cancer biotech Adlai Nortye Ltd. raised $57.5 million from its U.S. IPO on Nasdaq and $40 million from a concurrent private placement, ringing up $97.5 million in funding to develop its combo immunotherapy pipeline.
RSS
